Barclays Raises Hims & Hers Target After Novo Deal Clears
Barclays boosts its target on Hims & Hers Health as Novo Nordisk deal removes a key legal overhang, while Progyny see...
For long-term investing, focus on coins with clear use cases, strong teams, and growing demand. This guide highlights criteria to pick durable assets.
27,805 articlesBarclays boosts its target on Hims & Hers Health as Novo Nordisk deal removes a key legal overhang, while Progyny see...
SpaceX's market debut ignited a wave of aggressive bets on disruptive ideas. Investors pile into moonshot bets as opt...
Crypto.com cuts around staff by about 12%, eliminating roughly 180 roles as it refocuses on AI-enabled enterprise ser...
When a company’s top executive sells stock, investors want to know why. This deep dive explains BlackSky's sold over ...
Midwest apartment markets are turning brighter as rents rise and debt costs ease. BAM Capital now offers accredited i...
Could two of Elon Musk's biggest ventures consolidate into a market-shaking powerhouse? We dive into the rumors, the ...
Sarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Anthropic alleges Alibaba exploited thousands of fake accounts to copy AI outputs, prompting a swift stock reaction a...
Shield AI just unveiled a landmark Series G round worth $1.5 billion, lifting its valuation to $12.7 billion and sett...
Medicare will cover GLP-1 weight-loss drugs for eligible beneficiaries beginning this week, a policy shift that could...
When a global moment collides with everyday budgets, fans want to know how to enjoy it without breaking the bank. Thi...
A major Taiwan chipmaker plans to double the size of its Arizona facility, a move Trump touts as a potential steeplec...